EGFR and non-small cell lung carcinoma: In contemporary clinical practice, EGFR-TKIs such as osimertinib have been used as highly effective first-line chemotherapy for patients with NSCLC harboring sensitizing EGFR mutations (Ex19del or L858R) [2,3].